두 번째 의견을 준비할 때

source-backed record

Clinical trial search strategy

source-backed record

Nivolumab

source-backed record

Pembrolizumab

clinical-trial

Clinical trials in melanoma

Trial listings can show studies that mention a cancer, mutation, drug, or treatment history, but a listing match does not mean a study fits.

immunotherapy

Immune checkpoint inhibitors

Immunotherapy can help the immune system recognize and attack melanoma, but it can also cause immune-related side effects.

immunotherapy

Immune checkpoint inhibitors

Immunotherapy can help the immune system recognize and attack melanoma, but it can also cause immune-related side effects.

Phase 1/2 · completed

NCT03973151

Primary early clinical trial record for HL-085/tunlametinib in NRAS-mutant advanced melanoma.

This record is not the exact tunlametinib plus nivolumab combination remembered by the user.

Phase 3 · recruiting

NCT06008106

Phase III comparator trial after prior immunotherapy; useful for duration-of-response and trial-timing questions.

A trial listing match does not mean the trial fits. The trial team must confirm.

Phase 1/2 · unknown

NCT04375527

Supports the broader research concept of MEK inhibitor plus PD-1 inhibitor in melanoma, but not tunlametinib specifically.

Do not use this as evidence for tunlametinib plus nivolumab.

Phase 1 · unknown

NCT04835805

A sourced NRAS melanoma trial lead after anti-PD-1/PD-L1 therapy that may explain a remembered MEK/RAF plus PD-1 trial concept.

This is belvarafenib/cobimetinib/nivolumab, not tunlametinib/nivolumab.

Phase 1/2 · completed

NCT03979651

NRAS melanoma research lead involving MEK inhibition and autophagy inhibition.

Trial record does not make this a routine treatment option.